Alpha Tau Medical Reports Positive Clinical Trial Results
Ticker: DRTS · Form: 6-K · Filed: Apr 23, 2026 · CIK: 0001871321
Sentiment: bullish
Topics: clinical-trial-results, oncology, medical-technology
TL;DR
Alpha Tau's DLA tech shows strong results in CTCL & BCC trials, paving way for new cancer treatments.
AI Summary
Alpha Tau Medical Ltd. announced on April 23, 2026, positive results from two clinical trials. The ACAPELLA trial showed a 90% response rate in patients with unresectable, locally advanced, or metastatic cutaneous T-cell lymphoma (CTCL). The IMPACT trial demonstrated a 75% objective response rate in patients with unresectable, locally advanced, or metastatic basal cell carcinoma (BCC). These results are based on the use of Alpha Tau's proprietary Diffuse Laser Ablation (DLA) technology.
Why It Matters
Positive clinical trial outcomes for Alpha Tau's DLA technology could lead to new treatment options for patients with difficult-to-treat skin cancers, potentially improving patient outcomes and market share.
Risk Assessment
Risk Level: medium — While the trial results are positive, the company's success depends on further regulatory approvals and market adoption of its technology.
Key Numbers
- 90% — Response Rate (CTCL) (Achieved in the ACAPELLA trial for cutaneous T-cell lymphoma patients.)
- 75% — Objective Response Rate (BCC) (Demonstrated in the IMPACT trial for basal cell carcinoma patients.)
Key Players & Entities
- Alpha Tau Medical Ltd. (company) — Filer of the report and developer of DLA technology
- April 23, 2026 (date) — Date of the press releases and report period
- ACAPELLA (clinical_trial) — Trial name for cutaneous T-cell lymphoma
- IMPACT (clinical_trial) — Trial name for basal cell carcinoma
- Diffuse Laser Ablation (DLA) (technology) — Alpha Tau's proprietary medical technology
FAQ
What specific types of cutaneous T-cell lymphoma (CTCL) were treated in the ACAPELLA trial?
The ACAPELLA trial treated patients with unresectable, locally advanced, or metastatic cutaneous T-cell lymphoma (CTCL).
What was the objective response rate in the IMPACT trial for basal cell carcinoma (BCC)?
The IMPACT trial demonstrated a 75% objective response rate in patients with unresectable, locally advanced, or metastatic basal cell carcinoma (BCC).
What technology did Alpha Tau Medical use in these clinical trials?
Alpha Tau Medical used its proprietary Diffuse Laser Ablation (DLA) technology in both the ACAPELLA and IMPACT clinical trials.
When were the press releases regarding these trial results dated?
The press releases regarding the ACAPELLA and IMPACT clinical trial results were dated April 23, 2026.
What is Alpha Tau Medical Ltd.'s primary business according to the filing?
Alpha Tau Medical Ltd. is involved in Surgical & Medical Instruments & Apparatus, specifically with industrial applications and services.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 23, 2026 regarding Alpha Tau Medical Ltd. (DRTS).